Narcolepsy

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Narcolepsy is a neurologic disorder that is incurable and therefore requires lifelong treatment. Excessive daytime sleepiness is the most common symptom and can be partially controlled by medications. The pathognomonic symptom of narcolepsy is cataplexy, emotionally induced muscle weakness, which can be the most disabling symptom for many patients. Also, hallucinations that typically occur at sleep onset or muscle paralysis that occurs upon awakening from sleep, called sleep paralysis, occur in many patients. Additional symptoms include fragmented nocturnal sleep and episodes of automatic behavior. Narcolepsy typically has its onset in the first 2 decades of life and may commonly be misdiagnosed. It produces reduced quality of life and, because of the sleepiness, can interfere with memory, concentration, and other cognitive abilities. The cataplexy may predispose the patient to injury because of the muscle weakness or falls. Narcolepsy with cataplexy is now known to be associated with a loss of the hypothalamic neuropeptide hypocretin. An autoimmune basis for the disorder is suspected. Effective treatment of the symptoms usually requires medications although some patients manage their symptoms behaviorally. Most patients require the use of two or more medications, one to treat the daytime sleepiness and the other to control the cataplexy. With the recent availability of sodium oxybate, some patients can control both the daytime sleepiness and cataplexy with one medication.

Original languageEnglish (US)
Pages (from-to)101-114
Number of pages14
JournalCONTINUUM Lifelong Learning in Neurology
Volume13
Issue number3 SLEEP DISORDERS
DOIs
StatePublished - Jun 2007

Fingerprint

Narcolepsy
Cataplexy
Sleep
Muscle Weakness
Sleep Paralysis
Sodium Oxybate
Aptitude
Hallucinations
Nervous System Diseases
Diagnostic Errors
Neuropeptides
Paralysis
Quality of Life
Muscles
Wounds and Injuries
Therapeutics

ASJC Scopus subject areas

  • Clinical Neurology
  • Genetics(clinical)

Cite this

Narcolepsy. / Thorpy, Michael J.

In: CONTINUUM Lifelong Learning in Neurology, Vol. 13, No. 3 SLEEP DISORDERS, 06.2007, p. 101-114.

Research output: Contribution to journalArticle

Thorpy, Michael J. / Narcolepsy. In: CONTINUUM Lifelong Learning in Neurology. 2007 ; Vol. 13, No. 3 SLEEP DISORDERS. pp. 101-114.
@article{1f542c68dd0d46608df8c417693a5f15,
title = "Narcolepsy",
abstract = "Narcolepsy is a neurologic disorder that is incurable and therefore requires lifelong treatment. Excessive daytime sleepiness is the most common symptom and can be partially controlled by medications. The pathognomonic symptom of narcolepsy is cataplexy, emotionally induced muscle weakness, which can be the most disabling symptom for many patients. Also, hallucinations that typically occur at sleep onset or muscle paralysis that occurs upon awakening from sleep, called sleep paralysis, occur in many patients. Additional symptoms include fragmented nocturnal sleep and episodes of automatic behavior. Narcolepsy typically has its onset in the first 2 decades of life and may commonly be misdiagnosed. It produces reduced quality of life and, because of the sleepiness, can interfere with memory, concentration, and other cognitive abilities. The cataplexy may predispose the patient to injury because of the muscle weakness or falls. Narcolepsy with cataplexy is now known to be associated with a loss of the hypothalamic neuropeptide hypocretin. An autoimmune basis for the disorder is suspected. Effective treatment of the symptoms usually requires medications although some patients manage their symptoms behaviorally. Most patients require the use of two or more medications, one to treat the daytime sleepiness and the other to control the cataplexy. With the recent availability of sodium oxybate, some patients can control both the daytime sleepiness and cataplexy with one medication.",
author = "Thorpy, {Michael J.}",
year = "2007",
month = "6",
doi = "10.1212/01.CON.0000275607.54292.85",
language = "English (US)",
volume = "13",
pages = "101--114",
journal = "CONTINUUM Lifelong Learning in Neurology",
issn = "1080-2371",
publisher = "Lippincott Williams and Wilkins",
number = "3 SLEEP DISORDERS",

}

TY - JOUR

T1 - Narcolepsy

AU - Thorpy, Michael J.

PY - 2007/6

Y1 - 2007/6

N2 - Narcolepsy is a neurologic disorder that is incurable and therefore requires lifelong treatment. Excessive daytime sleepiness is the most common symptom and can be partially controlled by medications. The pathognomonic symptom of narcolepsy is cataplexy, emotionally induced muscle weakness, which can be the most disabling symptom for many patients. Also, hallucinations that typically occur at sleep onset or muscle paralysis that occurs upon awakening from sleep, called sleep paralysis, occur in many patients. Additional symptoms include fragmented nocturnal sleep and episodes of automatic behavior. Narcolepsy typically has its onset in the first 2 decades of life and may commonly be misdiagnosed. It produces reduced quality of life and, because of the sleepiness, can interfere with memory, concentration, and other cognitive abilities. The cataplexy may predispose the patient to injury because of the muscle weakness or falls. Narcolepsy with cataplexy is now known to be associated with a loss of the hypothalamic neuropeptide hypocretin. An autoimmune basis for the disorder is suspected. Effective treatment of the symptoms usually requires medications although some patients manage their symptoms behaviorally. Most patients require the use of two or more medications, one to treat the daytime sleepiness and the other to control the cataplexy. With the recent availability of sodium oxybate, some patients can control both the daytime sleepiness and cataplexy with one medication.

AB - Narcolepsy is a neurologic disorder that is incurable and therefore requires lifelong treatment. Excessive daytime sleepiness is the most common symptom and can be partially controlled by medications. The pathognomonic symptom of narcolepsy is cataplexy, emotionally induced muscle weakness, which can be the most disabling symptom for many patients. Also, hallucinations that typically occur at sleep onset or muscle paralysis that occurs upon awakening from sleep, called sleep paralysis, occur in many patients. Additional symptoms include fragmented nocturnal sleep and episodes of automatic behavior. Narcolepsy typically has its onset in the first 2 decades of life and may commonly be misdiagnosed. It produces reduced quality of life and, because of the sleepiness, can interfere with memory, concentration, and other cognitive abilities. The cataplexy may predispose the patient to injury because of the muscle weakness or falls. Narcolepsy with cataplexy is now known to be associated with a loss of the hypothalamic neuropeptide hypocretin. An autoimmune basis for the disorder is suspected. Effective treatment of the symptoms usually requires medications although some patients manage their symptoms behaviorally. Most patients require the use of two or more medications, one to treat the daytime sleepiness and the other to control the cataplexy. With the recent availability of sodium oxybate, some patients can control both the daytime sleepiness and cataplexy with one medication.

UR - http://www.scopus.com/inward/record.url?scp=34250725020&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250725020&partnerID=8YFLogxK

U2 - 10.1212/01.CON.0000275607.54292.85

DO - 10.1212/01.CON.0000275607.54292.85

M3 - Article

AN - SCOPUS:34250725020

VL - 13

SP - 101

EP - 114

JO - CONTINUUM Lifelong Learning in Neurology

JF - CONTINUUM Lifelong Learning in Neurology

SN - 1080-2371

IS - 3 SLEEP DISORDERS

ER -